Corgenix gets worldwide rights to Chugai liver test
This article was originally published in Clinica
Corgenix Medical has signed a technology agreement with Chugai Diagnostics Science, part of Chugai Pharmaceutical, gaining worldwide rights outside Japan to manufacture and market a microplate test that measures hyaluronic acid as a unique indicator of liver disease. International marketing of the test will be co-ordinated by Corgenix' UK subsidiary.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.